227 related articles for article (PubMed ID: 38193692)
1. An HTLV-1 envelope mRNA vaccine is immunogenic and protective in New Zealand rabbits.
Tu JJ; King E; Maksimova V; Smith S; Macias R; Cheng X; Vegesna T; Yu L; Ratner L; Green PL; Niewiesk S; Richner JM; Panfil AR
J Virol; 2024 Feb; 98(2):e0162323. PubMed ID: 38193692
[TBL] [Abstract][Full Text] [Related]
2. Highly attenuated HTLV type Ienv poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits.
Franchini G; Tartaglia J; Markham P; Benson J; Fullen J; Wills M; Arp J; Dekaban G; Paoletti E; Gallo RC
AIDS Res Hum Retroviruses; 1995 Feb; 11(2):307-13. PubMed ID: 7742044
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of rabbits with recombinant vaccinia virus carrying the envelope gene of human T-cell lymphotropic virus type I.
Hakoda E; Machida H; Tanaka Y; Morishita N; Sawada T; Shida H; Hoshino H; Miyoshi I
Int J Cancer; 1995 Feb; 60(4):567-70. PubMed ID: 7829272
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and protective efficacy of recombinant human T-cell leukemia/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus).
Kazanji M; Tartaglia J; Franchini G; de Thoisy B; Talarmin A; Contamin H; Gessain A; de Thé G
J Virol; 2001 Jul; 75(13):5939-48. PubMed ID: 11390595
[TBL] [Abstract][Full Text] [Related]
5. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
6. A Dengue Virus Serotype 1 mRNA-LNP Vaccine Elicits Protective Immune Responses.
Wollner CJ; Richner M; Hassert MA; Pinto AK; Brien JD; Richner JM
J Virol; 2021 May; 95(12):. PubMed ID: 33762420
[TBL] [Abstract][Full Text] [Related]
7. An HTLV-I/II vaccine: from animal models to clinical trials?
de Thé G; Kazanji M
J Acquir Immune Defic Syndr Hum Retrovirol; 1996; 13 Suppl 1():S191-8. PubMed ID: 8797723
[TBL] [Abstract][Full Text] [Related]
8. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
[TBL] [Abstract][Full Text] [Related]
9. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
[TBL] [Abstract][Full Text] [Related]
10. [Production of HTLV-II env protein and its suppressive effect on infection].
Kawamura N
Hokkaido Igaku Zasshi; 1995 Jul; 70(4):635-47. PubMed ID: 7590608
[TBL] [Abstract][Full Text] [Related]
11. In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations.
Silverman LR; Phipps AJ; Montgomery A; Fernandez S; Tsukahara T; Ratner L; Lairmore MD
Blood; 2005 Nov; 106(10):3602-8. PubMed ID: 16046523
[TBL] [Abstract][Full Text] [Related]
12. Nucleoside-Modified mRNA Vaccines Protect IFNAR
Appelberg S; John L; Pardi N; Végvári Á; Bereczky S; Ahlén G; Monteil V; Abdurahman S; Mikaeloff F; Beattie M; Tam Y; Sällberg M; Neogi U; Weissman D; Mirazimi A
J Virol; 2022 Feb; 96(3):e0156821. PubMed ID: 34817199
[TBL] [Abstract][Full Text] [Related]
13. Long-term persistence of protective immunity in cynomolgus monkeys immunized with a recombinant vaccinia virus expressing the human T cell leukaemia virus type I envelope gene.
Ibuki K; Funahashi SI; Yamamoto H; Nakamura M; Igarashi T; Miura T; Ido E; Hayami M; Shida H
J Gen Virol; 1997 Jan; 78 ( Pt 1)():147-52. PubMed ID: 9010298
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46.
Lairmore MD; Rudolph DL; Roberts BD; Dezzutti CS; Lal RB
Cancer Lett; 1992 Sep; 66(1):11-20. PubMed ID: 1360328
[TBL] [Abstract][Full Text] [Related]
15. Development of a cytotoxic T-cell assay in rabbits to evaluate early immune response to human T-lymphotropic virus type 1 infection.
Haynes RA; Phipps AJ; Yamamoto B; Green P; Lairmore MD
Viral Immunol; 2009 Dec; 22(6):397-405. PubMed ID: 19951176
[TBL] [Abstract][Full Text] [Related]
16. Kinetic analysis of human T-cell leukemia virus type 1 gene expression in cell culture and infected animals.
Li M; Kesic M; Yin H; Yu L; Green PL
J Virol; 2009 Apr; 83(8):3788-97. PubMed ID: 19193802
[TBL] [Abstract][Full Text] [Related]
17. Immunization with a murine cytomegalovirus based vector encoding retrovirus envelope confers strong protection from Friend retrovirus challenge infection.
Bongard N; Le-Trilling VTK; Malyshkina A; Rückborn M; Wohlgemuth K; Wensing I; Windmann S; Dittmer U; Trilling M; Bayer W
PLoS Pathog; 2019 Sep; 15(9):e1008043. PubMed ID: 31568492
[TBL] [Abstract][Full Text] [Related]
18. Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.
Iyer SS; Gangadhara S; Victor B; Shen X; Chen X; Nabi R; Kasturi SP; Sabula MJ; Labranche CC; Reddy PB; Tomaras GD; Montefiori DC; Moss B; Spearman P; Pulendran B; Kozlowski PA; Amara RR
J Virol; 2016 Oct; 90(19):8842-54. PubMed ID: 27466414
[TBL] [Abstract][Full Text] [Related]
19. Protection of rabbits against HTLV-II infection with a synthetic peptide corresponding to HTLV-II neutralization region.
Kariya N; Hayashi K; Hoshino H; Tanaka Y; Koirala TR; Ohara N; Miyamoto K; Akagi T
Arch Virol; 1996; 141(3-4):471-80. PubMed ID: 8645089
[TBL] [Abstract][Full Text] [Related]
20. Inclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.
Cox JH; Ferrari MG; Earl P; Lane JR; Jagodzinski LL; Polonis VR; Kuta EG; Boyer JD; Ratto-Kim S; Eller LA; Pham DT; Hart L; Montefiori D; Ferrari G; Parrish S; Weiner DB; Moss B; Kim JH; Birx D; VanCott TC
Vaccine; 2012 Feb; 30(10):1830-40. PubMed ID: 22234262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
